ADC Therapeutics SA Price to Free Cash Flow Ratio 2019-2022 | ADCT

Historical price to free cash flow ratio values for ADC Therapeutics SA (ADCT) since 2019. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
ADC Therapeutics SA Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2023-02-03 4.63 0.00
2022-09-30 4.82 $-1.89 0.00
2022-06-30 7.95 $-2.72 0.00
2022-03-31 14.69 $-2.80 0.00
2021-12-31 20.20 $-3.09 0.00
2021-09-30 27.16 $-3.21 0.00
2021-06-30 24.35 $-2.93 0.00
2021-03-31 24.41 $-3.32 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.376B $0.034B
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $154.721B 9.45
GSK (GSK) United Kingdom $71.915B 9.49
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.215B 19.14
Ginkgo Bioworks Holdings (DNA) United States $4.249B 0.00
Myovant Sciences (MYOV) United Kingdom $2.615B 0.00
Arcus Biosciences (RCUS) United States $1.532B 23.00
Biohaven (BHVN) United States $1.307B 0.00
Emergent Biosolutions (EBS) United States $0.726B 5.71
Ambrx Biopharma (AMAM) United States $0.071B 0.00
Enzo Biochem (ENZ) United States $0.067B 0.00
SQZ Biotechnologies (SQZ) United States $0.023B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00